Wandercraft Acquires Ekso Bionics, Uniting Two Pioneers to Advance and Expand Robotic Mobility
Key Highlights
- ➤Wandercraft acquires Ekso Bionics from ChronoScale Holdings (CHRN) subsidiary
- ➤Transaction signed and closed simultaneously after unanimous board approval
- ➤Combined platforms support patients at more than 700 rehabilitation centers worldwide
- ➤Atalante X and EksoNR hold U.S. FDA clearances and CE marking
- ➤Financial terms were not disclosed
Expert Statements
Matthieu Masselin, CEO and co-founder of Wandercraft
“We share a vision for how robotics can empower people whose mobility has been unfairly limited by injury or disease”
Matthieu Masselin, CEO and co-founder of Wandercraft
“Both companies have pioneered advanced technologies to help people stand, walk, and participate more fully in everyday life. By bringing together our products, teams, and clinical relationships on both sides of the Atlantic, we have an exceptional opportunity to expand access to robotic mobility worldwide, reach more patients and rehabilitation professionals, and help more people experience the independence and connection that upright mobility can offer.”
Scott Davis, of the go-forward Ekso Bionics
“Ekso has spent two decades pioneering robotic technologies, advancing engineering and R&D, and building a robust body of clinical research and evidence that has earned the trust of clinicians and the people who rely on our products.”
Scott Davis, of the go-forward Ekso Bionics
“Joining Wandercraft represents an exciting next chapter, uniting two organizations with a shared commitment to mobility, rehabilitation, and innovation. Together, we can build on that trailblazing work and expand our ability to develop and deploy technologies that make a meaningful difference for more people.”
NEW YORK and SAN RAFAEL, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Wandercraft today announced the acquisition of Ekso Bionics, Inc. from a subsidiary of ChronoScale Holdings Corporation (Nasdaq: CHRN), bringing together two leaders in robotic mobility. The two companies contribute complementary technologies and decades of combined experience to help more people to stand, walk, and participate more fully in everyday life. Together, they form the world’s leading medical exoskeleton company, offering an unmatched combination of technology, clinical experience, and global reach.
The acquisition combines Wandercraft’s expertise in advanced robotics and physical AI and its leadership in EMEA with Ekso Bionics’ strong U.S. presence, extensive clinical experience, and commercial reach. Both companies have been trailblazers in medical exoskeletons, driving technological innovation, R&D, and clinical research. The combination creates a global powerhouse in robotic mobility, with a broader portfolio of medical exoskeletons spanning the continuum of care, from rehabilitation to everyday personal mobility.
Get started
Create a free account to read the full story.